Exicure Inc (XCUR) USD0.0001
Exicure, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for immuno-oncology, genetic disorders and other indications based on its Spherical Nucleic Acid (SNA) technology. SNA is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Its pipeline includes AST-008, XCUR-FXN and XCUR17. AST-008 product is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. XCUR-FXN is a preclinical program for the treatment of Friedreich’s ataxia (FA). XCUR17 is being developed for inflammatory disorders, netherton syndrome and hair loss disorders. XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha (IL-17RA).
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.